Unknown

Dataset Information

0

Potent immunomodulation and angiogenic effects of mesenchymal stem cells versus cardiomyocytes derived from pluripotent stem cells for treatment of heart failure.


ABSTRACT:

Background

Optimal cell type as cell-based therapies for heart failure (HF) remains unclear. We sought to compare the safety and efficacy of direct intramyocardial transplantation of human embryonic stem cell-derived cardiomyocytes (hESC-CMs) and human induced pluripotent stem cell-derived mesenchymal stem cells (hiPSC-MSCs) in a porcine model of HF.

Methods

Eight weeks after induction of HF with myocardial infarction (MI) and rapid pacing, animals with impaired left ventricular ejection fraction (LVEF) were randomly assigned to receive direct intramyocardial injection of saline (MI group), 2?×?108 hESC-CMs (hESC-CM group), or 2?×?108 hiPSC-MSCs (hiPSC-MSC group). The hearts were harvested for immunohistochemical evaluation after serial echocardiography and hemodynamic evaluation and ventricular tachyarrhythmia (VT) induction by in vivo programmed electrical stimulation.

Results

At 8?weeks post-transplantation, LVEF, left ventricular maximal positive pressure derivative, and end systolic pressure-volume relationship were significantly higher in the hiPSC-MSC group but not in the hESC-CM group compared with the MI group. The incidence of early spontaneous ventricular tachyarrhythmia (VT) episodes was higher in the hESC-CM group but the incidence of inducible VT was similar among the different groups. Histological examination showed no tumor formation but hiPSC-MSCs exhibited a stronger survival capacity by activating regulatory T cells and reducing the inflammatory cells. In vitro study showed that hiPSC-MSCs were insensitive to pro-inflammatory interferon-gamma-induced human leukocyte antigen class II expression compared with hESC-CMs. Moreover, hiPSC-MSCs also significantly enhanced angiogenesis compared with other groups via increasing expression of distinct angiogenic factors.

Conclusions

Our results demonstrate that transplantation of hiPSC-MSCs is safe and does not increase proarrhythmia or tumor formation and superior to hESC-CMs for the improvement of cardiac function in HF. This is due to their immunomodulation that improves in vivo survival and enhanced angiogenesis via paracrine effects.

SUBMITTER: Liao S 

PROVIDER: S-EPMC6407247 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Potent immunomodulation and angiogenic effects of mesenchymal stem cells versus cardiomyocytes derived from pluripotent stem cells for treatment of heart failure.

Liao Songyan S   Zhang Yuelin Y   Ting Sherwin S   Zhen Zhe Z   Luo Fan F   Zhu Ziyi Z   Jiang Yu Y   Sun Sijia S   Lai Wing-Hon WH   Lian Qizhou Q   Tse Hung-Fat HF  

Stem cell research & therapy 20190307 1


<h4>Background</h4>Optimal cell type as cell-based therapies for heart failure (HF) remains unclear. We sought to compare the safety and efficacy of direct intramyocardial transplantation of human embryonic stem cell-derived cardiomyocytes (hESC-CMs) and human induced pluripotent stem cell-derived mesenchymal stem cells (hiPSC-MSCs) in a porcine model of HF.<h4>Methods</h4>Eight weeks after induction of HF with myocardial infarction (MI) and rapid pacing, animals with impaired left ventricular e  ...[more]

Similar Datasets

| S-EPMC9312476 | biostudies-literature
| S-EPMC6224789 | biostudies-literature
| S-EPMC8422924 | biostudies-literature
| S-EPMC4086362 | biostudies-literature
| S-EPMC3966242 | biostudies-literature
| S-EPMC4281179 | biostudies-literature
| S-EPMC2096777 | biostudies-literature
| S-EPMC4460911 | biostudies-literature
| S-EPMC2741334 | biostudies-literature
| S-EPMC4816164 | biostudies-literature